Global pharma major Lupin Limited (Lupin) announced the launch of rufinamide tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel tablets, 200 mg and 400 mg, of Eisai Inc.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
